STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)

Completed · Phase 2 · Has a placebo group

Conditions studied: Heart Failure

In brief

This research study will test whether atorvastatin, a drug commonly prescribed for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin. Atorvastatin is from a family of medications that are commonly called "statins"

Key facts

Study ID

NCT02943590

Run by

Massachusetts General Hospital

People needed

300

Starts

2017-01-13

Expected to finish

2023-10-11

Last updated by the study team

2025-05-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• > 18 years of age
• All patients with newly diagnosed NHL and HL
• Scheduled to receive anthracycline-based therapy

You may not qualify if…

• Statin use or Statin use is indicated based on guidelines
• Pregnancy or breastfeeding
• Unable to provide informed consent
• Unexplained persistent elevation of transaminases (>3 times upper limits of normal)
• Concomitant use of cyclosporine
• Renal failure: estimated glomerular filtration <45 mL/min/1.73 m2
• Contraindication to a CMR (metallic object, severe claustrophobia, pacemaker, vascular clip
• LVEF of <50% at baseline

Where it is running

• Massachusetts general Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• University of Pennsylvania Medical System — Philadelphia, Pennsylvania, United States
• McGill University Health Center — Toronto, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.